Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.90, $0.04 better than the analyst estimate of $2.86. Revenue for the quarter came in at $25.31 billion versus the consensus estimate of $25.02 billion.

GUIDANCE:

Johnson & Johnson sees FY2026 EPS of $11.50-$11.65, versus the consensus of $11.58. Johnson & Johnson sees FY2026 revenue of $100.8-101.4 billion, versus the consensus of $101.06 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Goldcana closes C$2M private placement, issues 8M units
• HeartSciences (HSCS) files $200M mixed shelf